Learn how AbbVie could help you save on IMBRUVICA®. Call 1-866-IMBRUVICA or click to learn more >

hero background image

IMBRUVICA® has helped many adults with CLL/SLL live longer*

In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib) died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*

Here’s to more time together and the opportunity to keep doing what you love.

Here's to the life in your years

CLL=chronic lymphocytic leukemia;
SLL=small lymphocytic lymphoma.
Arrow

Here’s to saving on IMBRUVICA®

You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card. Subject to eligibility; restrictions apply.

Enroll Now

Receive one-on-one support plus financial and educational resources to help start and stay on track with IMBRUVICA®

Explore Support Options

Understanding your CLL diagnosis

Learn more about genetic testing and CLL

Learn More
About CLL/SLL

IMBRUVICA® for CLL

Questions to ask your doctor about CLL and IMBRUVICA®

Get More Information
About IMBRUVICA® for CLL

Learn from a patient

Real stories from CLL patients about their experience with IMBRUVICA®

View Patient
Videos Here

In one clinical trial of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.

Welcome to a different way of treating CLL/SLL

Starting treatment is an important time in your journey with CLL/SLL. This website will help you learn more about your condition and how IMBRUVICA® can help.

IMBRUVICA® works differently from chemotherapy. This once-daily, oral medication blocks a protein in B cells called Bruton's tyrosine kinase, or BTK. For more complete information on how IMBRUVICA® works and the possible side effects, go to the How Does IMBRUVICA® Work? section.1
 

With IMBRUVICA®, there’s a once-daily oral treatment option available to treat CLL/SLL1


IMBRUVICA® is a prescription medicine used to treat adults with:

  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion

It is not known if IMBRUVICA® is safe and effective in children.

Thinking about treatment with IMBRUVICA®?

Sign up today to receive the latest information and helpful resources.

From the moment you’re prescribed IMBRUVICA®, IMBRUVICA® By Your Side provides resources and support for getting the help you may need during treatment.*

Coverage and Cost

Confirm your coverage and out-of-pocket costs for IMBRUVICA®.

Support Communications

Receive periodic emails with tips and information about treatment.

IMBRUVICA® By Your Side Ambassadors*

Call a By Your Side Ambassador if you have questions about IMBRUVICA®.

Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call 1-888-968-7743 for additional information. For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.
 

IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2National Institutes of Health. BTK gene. Accessed June 6, 2023. https://medlineplus.gov/genetics/gene/btk/

Pharmacyclics, an AbbVie Company, may collect your personal data through your online and offline interactions with us, including your contact, demographic, geolocation, and health-related data. We may also collect your online usage data automatically through cookies and similar technologies. We use this data for several purposes, such as to provide you with and improve our programs, services, and products, customize your experiences, and for research and analytics. We retain your personal data for as long as necessary to fulfill these purposes or to comply with our record retention obligations. We do not sell your personal data but may use and disclose your personal data with marketing and advertising partners to deliver you ads based on your interests inferred from your activity across other unaffiliated sites and services (“online targeted advertising”) and for website analytics. To opt out of the use or disclosure of your personal data for online targeted advertising or for website analytics, go to Your Privacy Choices on our website. For more information on the personal data categories we collect, the purposes for their collection, our disclosures to third parties, your data subject rights, and our data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose Personal Data section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at
https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm).